（原标题：哥伦比亚媒体呼吁中哥加强生物科技合作） 据哥伦比亚《证券报》11月13日报道，哥凭借独特的生物多样性和逾3300 个成熟科研团队，具备发展生物经济的关键基础。然而，本土创新仍面临"能 研究、难规模化"的瓶颈，科研成果多停留在论文与展示阶段，难以转化为产 业和出口。在全球生物产业加速布局之际，中国正成为生物制造的重要中心， 其优势不仅在于成本，更体现在规模化生产、资本投入及完善的实验室—工厂 —认证体系，这正是哥所缺乏的环节。业内认为，哥生物资源与科研能力与中 国的产业化与技术转移优势高度互补。哥应与中国推动以产业化为导向的合 作，建立涵盖知识产权共享、技术培训、本地化生产等明确规则，并强化治 理、谈判和监管能力，以确保合作可持续。专家指出，哥正处于从"展示型创 新"迈向"产业化创新"的关键阶段，应抓住与中国深化合作的机会，构筑生物 产业竞争优势。 ...

| 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 207.70 | -0.24% | | 2518.24 | 医药生物 | | sz000661 | 长春高新 | 4.87% | 104.55 | 0.09% | | 426.50 | 医药生物 | | sz002252 | 十年奥士 | 4.74% | 6.87 | -0.43% | | 456.03 | 医药生物 | | sz300759 | 康龙化成 | 4.55% | 31.48 | -0.35% | | 559.78 | 医药生物 | | sz300347 | 泰格医药 | 4.54% | 57.90 | -2.08% | | 498.53 | 医药生物 | | sz000021 | 深科技 | 4.16% | 24.74 | -5.43% | | 388.83 | 电子 | | sz002714 | 牧原股份 | 3.62% | 49.87 ...

Group 1 - The core viewpoint of the article emphasizes the importance of a modern industrial system as the material and technological foundation for Chinese-style modernization and high-quality revitalization and development [1] - The "15th Five-Year Plan" proposed by the Heilongjiang Provincial Committee aims to accelerate the development of digital economy, bio-economy, ice and snow economy, and creative design industries, targeting a total scale of 1 trillion yuan for these four new engine industries [1] - Heilongjiang has a strong industrial foundation, with the revitalization and development rooted in the real economy and focused on industrial upgrading [1] Group 2 - The plan aims to create emerging pillar industries and expand high-end equipment, aerospace, and new materials into billion-level industrial clusters, with a goal of achieving a total scale of 500 billion yuan for strategic emerging industries such as aerospace, electronic information, new materials, high-end equipment, and intelligent agricultural machinery [1] - The proposal also emphasizes the need to promote traditional industries from primary processing to deep processing, developing intelligent and green manufacturing, and strengthening the national energy and raw materials base, with a target of exceeding 1 trillion yuan for traditional advantageous industries like energy, chemicals, food, pharmaceuticals, automobiles, and light industry [2] - The plan includes actions to enhance the capacity and quality of the service industry, promoting specialized and high-value-added production services such as technology services, software and information technology services, and e-commerce, aiming for a total scale of 800 billion yuan for service industries like information services, modern logistics, and modern finance [2]

证券之星消息，11月10日，生物经济（970038）指数报收于2270.57点，涨1.89%，成交270.83亿元，换 手率1.74%。当日该指数成份股中，上涨的有47家，九安医疗以10.01%的涨幅领涨，下跌的有3家，福瑞 股份以1.75%的跌幅领跌。 生物经济（970038）指数十大成份股详情如下： 资金流向方面，生物经济（970038）指数成份股当日主力资金净流入合计15.05亿元，游资资金净流出合 计4.17亿元，散户资金净流出合计10.87亿元。成份股资金流向详情见下表： | 证券代码 | 股票简称 | 权重 | 最新价 | 涨跌幅 | 总市值(亿元) | 所属行业 | | --- | --- | --- | --- | --- | --- | --- | | sz300760 | 迈瑞医疗 | 12.58% | 209.35 | 1.73% | 2538.25 | > 医药生物 | | sz000661 | 长春高新 | 4.87% | 105.06 | 0.54% | 428.58 | 医药生物 | | sz002252 | 十体奥上 | 4.74% | 6.91 | 0.44% | 458.6 ...

Group 1 - The Biotech Index (970038) closed at 2277.73 points, down 0.07%, with a trading volume of 25.957 billion yuan and a turnover rate of 1.67% [1] - Among the index constituents, 26 stocks rose, led by Meiya Optoelectronics with a 3.74% increase, while 22 stocks fell, with Hualan Biological leading the decline at 3.87% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, Changchun High-tech, and Kanglong Chemical, with varying weightings and market capitalizations [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 190 million yuan, while retail funds saw a net outflow of 143 million yuan, and speculative funds had a net inflow of 334 million yuan [3] - Specific stock fund flows indicate that Muyuan Foods had a main fund net inflow of 14.7 million yuan, while Mindray Medical experienced a main fund net inflow of 69.649 million yuan [3] - The data shows a mixed trend in fund flows, with some stocks attracting significant speculative interest while others faced outflows from both main and retail investors [3]

Core Insights - The Biotech Index (970038) closed at 2279.35 points, up 0.77%, with a trading volume of 28.709 billion yuan and a turnover rate of 1.85% [1] - Among the index constituents, 41 stocks rose, with Hualan Vaccine leading at a 17.88% increase, while 8 stocks fell, with Deep Technology leading the decline at 6.38% [1] Index Performance - The Biotech Index saw a net inflow of 140 million yuan from institutional investors, while retail investors contributed a net inflow of 210 million yuan, and there was a net outflow of 350 million yuan from speculative funds [1] Top Constituents - The top ten constituents of the Biotech Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 215.04, and a decrease of 0.76% [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 112.26, and a decrease of 2.55% [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 33.51, and an increase of 1.12% [1] - Other notable constituents include Muyuans (sz002714) and Aimeike (sz300896) with respective weights of 3.66% and 3.44% [1] Capital Flow Details - Detailed capital flow for key stocks includes: - Mindray Medical saw a net inflow of 26.2 million yuan from institutional investors [2] - Muyuans had a net inflow of 203 million yuan from institutional investors [2] - Hualan Vaccine experienced a net inflow of 74.8 million yuan from institutional investors [2]

Core Insights - The Biotech Economy Index (970038) closed at 2298.38 points, up 0.92%, with a trading volume of 24.11 billion yuan and a turnover rate of 1.39% [1] - Among the index constituents, 27 stocks rose while 22 fell, with Tigermed leading the gainers at 11.09% and Kaili Medical leading the decliners at 11.39% [1] Index Performance - The Biotech Economy Index had a net inflow of 169 million yuan from institutional investors, while retail investors experienced a net outflow of approximately 79.92 million yuan [1][2] - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, latest price 222.83 yuan, market cap 270.17 billion yuan) [1] - Changchun High-tech (5.41% weight, latest price 117.55 yuan, market cap 47.95 billion yuan) [1] - Kanglong Chemical (4.66% weight, latest price 34.05 yuan, market cap 60.55 billion yuan) [1] - Tigermed (4.23% weight, latest price 59.48 yuan, market cap 51.21 billion yuan) [1] - Other notable constituents include Deep Technology, Muyuan Foods, and Aimeike [1] Capital Flow Analysis - The capital flow details indicate that Deep Technology had a net inflow of 201 million yuan from institutional investors, while retail investors saw a significant outflow of 222 million yuan [2] - Kanglong Chemical and Tigermed also experienced net inflows from institutional investors, but faced outflows from retail investors [2] - Overall, the data suggests a mixed sentiment among different investor classes within the Biotech Economy Index [2]

Core Insights - The Biotech Economy Index (970038) closed at 2261.4 points, down 0.81%, with a trading volume of 16.635 billion yuan and a turnover rate of 1.19% [1] - Among the index constituents, 19 stocks rose while 30 stocks fell, with Meihao Medical leading the gainers at 6.53% and Prolo Pharma leading the decliners at 5.41% [1] Index Performance - The Biotech Economy Index experienced a decline of 0.81% on the reporting day [1] - The total market capitalization of the index constituents was significant, with major players like Mindray Medical valued at 266.98 billion yuan [1] Top Constituents - The top ten constituents of the Biotech Economy Index include: - Mindray Medical (13.81% weight, 220.20 yuan, -1.51% change, 2669.80 billion yuan market cap) [1] - Changchun High-tech (5.41% weight, 119.11 yuan, -0.97% change, 485.89 billion yuan market cap) [1] - Kanglong Chemical (4.66% weight, 30.96 yuan, +0.29% change, 550.53 billion yuan market cap) [1] - Other notable constituents include Taige Pharmaceutical, Muyuans, and Aimeike, all within the biotech and healthcare sectors [1] Capital Flow - The net outflow of main funds from the Biotech Economy Index constituents totaled 0.893 billion yuan, while retail investors saw a net inflow of 0.75 billion yuan [1] - Specific stocks like Kanglong Chemical and Meihao Medical experienced varying levels of net inflow and outflow from different investor categories [2]

Investment Rating - The report does not explicitly state an investment rating for the synthetic biology industry Core Insights - The synthetic biology sector is experiencing a global biotechnology revolution, providing innovative solutions to major challenges such as health, climate change, and food security, as highlighted by the National Development and Reform Commission's "14th Five-Year Plan for Bioeconomic Development" [4] - The Huazhong Securities Synthetic Biology Index, which includes 58 companies involved in synthetic biology, has seen a decline of 4.96% recently, indicating a performance lag compared to the Shanghai Composite Index [5][22] Summary by Sections 1. Synthetic Biology Market Dynamics - The synthetic biology sector's stocks fell by 4.96% in the week of October 13-17, 2025, ranking 24th among sectors [22] - The top five gainers in this sector included Yuanli Technology (+11%) and Fuxiang Pharmaceutical (+11%), while the top five losers included Shengquan Group (-18%) and Jinziham (-18%) [23][27] 2. Company Business Developments - Huada Zhizao has signed a licensing agreement to expand its sequencing technology into the European and American markets [28] - Haineng Energy has been approved to enter the bio-aviation fuel "white list," allowing it to produce 158,000 tons of bio-aviation fuel annually [29] - Jinggong Holdings is set to launch a 50,000-ton green recycled material production line, which will be the largest chemical recycling polyester enterprise globally [30] 3. Industry Financing Tracking - The synthetic biology sector has seen accelerated financing, with nearly 100 companies completing new funding rounds in 2025 [35] - Zhejiang Ruiwei New Materials Technology Co., Ltd. completed a multi-million yuan financing round, focusing on biodegradable materials for the beauty and textile industries [35]

Core Points - The Bioeconomy Index (970038) closed at 2262.82 points, up 0.08%, with a trading volume of 19.253 billion yuan and a turnover rate of 1.3% [1] - Among the index constituents, 27 stocks rose, with Iwubio leading at a 10.07% increase, while 22 stocks fell, with Yifan Pharmaceutical leading the decline at 4.45% [1] Index Constituents Summary - The top ten constituents of the Bioeconomy Index include: - Mindray Medical (sz300760) with a weight of 13.81%, latest price at 223.47, down 0.90%, and a market cap of 270.944 billion yuan [1] - Changchun High-tech (sz000661) with a weight of 5.41%, latest price at 121.12, down 0.12%, and a market cap of 49.409 billion yuan [1] - Kanglong Chemical (sz300759) with a weight of 4.66%, latest price at 30.56, up 1.76%, and a market cap of 54.342 billion yuan [1] - Shizhu Aoshi (sz002252) with a weight of 4.52%, latest price at 6.67, up 0.15%, and a market cap of 44.275 billion yuan [1] - Biao Ge Shi Medicine (sz300347) with a weight of 4.23%, latest price at 54.08, up 0.95%, and a market cap of 46.564 billion yuan [1] - Shenzhen Technology (sz000021) with a weight of 4.08%, latest price at 27.24, down 0.58%, and a market cap of 42.693 billion yuan [1] - Muyuan Foods (sz002714) with a weight of 3.66%, latest price at 49.48, down 2.25%, and a market cap of 270.298 billion yuan [1] - Aimeike (sz300896) with a weight of 3.44%, latest price at 167.03, down 1.49%, and a market cap of 50.542 billion yuan [1] - Kailai Ying (sz002821) with a weight of 3.23%, latest price at 105.80, up 2.72%, and a market cap of 38.151 billion yuan [1] - Color Egg Therapy (sz002223) with a weight of 3.19%, latest price at 36.65, down 1.24%, and a market cap of 36.741 billion yuan [1] Capital Flow Summary - The Bioeconomy Index constituents experienced a net outflow of 599 million yuan from institutional investors and 215 million yuan from retail investors, while retail investors saw a net inflow of 814 million yuan [3] - Notable capital flows include: - Kanglong Chemical saw a net inflow of 74.766 million yuan from institutional investors, while retail investors experienced a net outflow of 49.703 million yuan [3] - Hualan Biological had a net inflow of 42.164 million yuan from institutional investors, with retail investors seeing a net outflow of 33.5328 million yuan [3] - Lepu Medical had a net inflow of 40.927 million yuan from institutional investors, while retail investors had a net outflow of 32.1814 million yuan [3] - Kailai Ying had a net inflow of 38.867 million yuan from institutional investors, with retail investors experiencing a net outflow of 16.4533 million yuan [3] - Iwubio had a net inflow of 23.192 million yuan from institutional investors, while retail investors saw a net outflow of 5.9208 million yuan [3]